Want to see ADOCY full AI Analyst Report?
Adocia (ADOCY) AI Stock Analysis
Adocia
(Other OTC:ADOCY)
The score is held down primarily by weak financial performance—persistent losses, cash burn, and elevated leverage—combined with a clearly bearish technical setup (price below all key moving averages and negative MACD). Valuation provides limited support due to the company being loss-making and the absence of a dividend yield.
Adocia (ADOCY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $170.44M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -13.0
- Beta (1Y)
- 1.10
- Revenue Growth
- -94.94%
- EPS Growth
- -57.40%
- Country
- US
- Employees
- 78
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Adocia Business Overview & Revenue Model
Company Description
Adocia S.A. is a clinical-stage biotechnology company dedicated to the research and development of novel formulations of established therapeutic proteins and peptides. Its primary focus is on addressing diabetes and various other metabolic disorders....
How the Company Makes Money
Adocia’s business model is primarily that of a clinical-stage biotech focused on partnering and licensing rather than large-scale in-house commercialization. The company historically generates revenue mainly from (1) collaboration and licensing agree...
Adocia Financial Statement Overview
Summary
Financial fundamentals are very weak: persistent net losses with extremely negative margins, highly volatile revenue (sharp decline in 2025 after a strong 2024), and ongoing negative operating/free cash flow indicating continued cash burn. Balance sheet risk is elevated due to historically negative equity and still-high leverage even after equity turned positive in 2025.
Income Statement
12Very NegativeBalance Sheet
18Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.42M | 1.42M | 9.32M | 1.95M | 11.45M | 1.44M |
| Gross Profit | -9.29M | 0 | 8.20M | 1.26M | 9.61M | 180.00K |
| EBITDA | -9.18M | -16.93M | -6.91M | -17.54M | -3.58M | -19.35M |
| Net Income | -15.94M | -15.94M | -9.32M | -19.23M | -6.90M | -22.75M |
Balance Sheet | ||||||
| Total Assets | 28.44M | 28.44M | 27.02M | 24.96M | 30.61M | 30.05M |
| Cash, Cash Equivalents and Short-Term Investments | 17.25M | 17.25M | 7.53M | 12.96M | 17.42M | 15.16M |
| Total Debt | 8.90M | 8.90M | 11.83M | 13.09M | 33.21M | 34.48M |
| Total Liabilities | 26.95M | 26.95M | 30.11M | 31.87M | 43.58M | 43.87M |
| Stockholders Equity | 1.49M | 1.49M | -3.09M | -6.91M | -12.97M | -13.81M |
Cash Flow | ||||||
| Free Cash Flow | -6.77M | -6.53M | -15.84M | -5.11M | -15.15M | -19.59M |
| Operating Cash Flow | -6.51M | -6.27M | -15.61M | -4.95M | -14.99M | -19.23M |
| Investing Cash Flow | -273.56K | -264.14K | -258.00K | -138.00K | 21.86M | -361.00K |
| Financing Cash Flow | 16.43M | 15.87M | 10.44M | 629.00K | -4.61M | 6.64M |
Adocia Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADOCY, the sentiment is Neutral. The current price of 3.38 is above the 20-day moving average (MA) of 2.67, below the 50-day MA of 3.54, and below the 200-day MA of 5.26, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 59.21 is Neutral, neither overbought nor oversold. The STOCH value of 94.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ADOCY.
Adocia Peers Comparison
Overall Rating
CBIO48Neutral
ACHV47Neutral
FATE47Neutral
CCCC41Neutral- ADOCY40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| CBIO | 48Neutral | $500.70M | -1.78 | -97.77% | ― | ― | 78.59% |
| ACHV | 47Neutral | $702.82M | -4.41 | -892.07% | ― | ― | -6.14% |
| FATE | 47Neutral | $249.23M | -1.98 | -65.08% | ― | -23.36% | 27.52% |
| CCCC | 41Neutral | $414.59M | -3.37 | -45.45% | ― | 2.33% | 36.86% |
| ADOCY | 40Underperform | $74.32M | -13.00 | -3666.80% | ― | -94.94% | -57.40% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ADOCY | Adocia SA | 3.38 | -6.89 | -67.08% | |
| ACHV | Achieve Life Sciences | 6.83 | 1.72 | 33.66% | |
| FATE | Fate Therapeutics Inc | 2.08 | 0.82 | 65.08% | |
| CBIO | Crescent Biopharma, Inc. | 13.48 | 1.13 | 9.15% | |
| CCCC | C4 Therapeutics, Inc. | 3.37 | 0.89 | 35.89% | |
| ACTU | Actuate Therapeutics, Inc. | 0.34 | -6.37 | -95.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 26, 2026